TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03437590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942
Description: JNJ-55308942 will be administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942
Description: JNJ-55308942 will be administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-JNJ-64413739
Description: \[18F\]-JNJ-64413739 fluid for injection administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-JNJ-64413739
Description: \[18F\]-JNJ-64413739 fluid for injection administered intravenously.
Study: NCT01927679

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin E

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin E

Intervention type: DRUG
Group type: OTHER
Intervention: Eucerin
Description: Control

Intervention type: DRUG
Group type: OTHER
Intervention: Eucerin
Description: Control
Study: NCT03620721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness
Description: 8-week mindfulness based group intervention
Study: NCT03322826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: systematic sampling of the lymph-node
Description: Systematic Sampling of lymph nodes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymphadenectomy
Description: Routine lymph nodes dissection in lung cancer
Study: NCT00509418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid
Description: Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric Diet with controlled exercise
Description: Modified ADA diet in combination with controlled exercise daily 24 weeks
Study: NCT01356953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Intensity of aerobic exercise
Study: NCT03708588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Chewed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Integral
Study: NCT02757482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training
Study: NCT03971838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Outcomes for Women
Description: Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight.
Study: NCT04712201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En bloc transurethral resection of bladder tumor (TURBT)
Description: En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TURBT
Description: Conventional transurethral resection of bladder tumor using monopolar and bipolar energy
Study: NCT03570983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
Study: NCT00891306

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
Description: intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral, 2 g/day, day -3 till week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: oral, 3 mg/kg/day, day -3 till week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
Study: NCT01391325

Intervention type: DRUG
Group type: OTHER
Intervention: Allopurinol
Description: Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
Study: NCT00603265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03131635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental Reciprocity Treatment Program (DRT-P)
Description: Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
Study: NCT05287425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Ophthalmic
Description: 4 drops daily in both eyes for 7 ± 1 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Ophthalmic
Description: 4 drops daily in both eyes for 7 ± 1 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone Ophthalmic
Description: 4 drops daily in both eyes for 7 ± 1 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone and Benzalkonium Chloride Ophthalmic
Description: 4 drops daily in both eyes for 7 ± 1 days
Study: NCT03102125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: For use in stress myocardial perfusion imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: For use in stress myocardial perfusion imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: For use in stress myocardial perfusion imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: For use in stress myocardial perfusion imaging.
Study: NCT02966002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT05340751

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood drawn
Description: Hemoglobin and Hematocrit Levels
Study: NCT01862822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upright position
Study: NCT03311763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIM Fitness Practitioners
Description: Exercise is Medicine Practitioners will facilitate peer groups that attend twice-weekly exercise classes for 8 weeks, with clinical monitoring and advise regarding increasing physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling and wearable device
Description: Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling and wearable device
Description: Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
Study: NCT02110732

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus rhamnosus GG

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus rhamnosus GG
Study: NCT01073800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 80 mg per os daily
Description: atorvastatin 80 mg per os daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02425748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: DC-CIK cells will be used against tumor cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T Cell
Description: γδ T cells will be used against non small lung tumor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T/DC-CIK cells
Description: γδ T/DC-CIK cells will be used against lung tumor.
Study: NCT02825901

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ingest placebo drink 100ml/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ingest placebo drink 100ml/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Djulis-Buckwheat
Description: Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Djulis-Buckwheat
Description: Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Buckwheat
Description: Ingest Buckwheat drink 100ml/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buckwheat
Description: Ingest Buckwheat drink 100ml/day for 8 weeks
Study: NCT00039325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell-MART-1 peptide vaccine
Description: Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell-MART-1 peptide vaccine
Description: Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell-MART-1 peptide vaccine
Description: Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell-MART-1 peptide vaccine
Description: Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell-MART-1 peptide vaccine
Description: Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
Study: NCT04437225

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low oxalate controlled Diet
Description: Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low oxalate controlled Diet
Description: Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low oxalate controlled Diet
Description: Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primed, continuous intravenous infusion of 13C2-Glycolate
Description: Participants will receive a continuous intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, over the course of several hours until steady-state is achieved, using an IV catheter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus intravenous infusion of 13C2-Glycolate
Description: Participants will receive a bolus intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, using an IV catheter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral bolus administration of 13C2-Glycolate
Description: Participants will orally ingest a single dose of carbon-13 glycolate, a naturally occurring form of glycolate.
Study: NCT03491345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab 10mg/kg, IV, q 2 weeks
Study: NCT03497507

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham bracelet
Description: Patients will wear bracelets on both hands

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure bracelet
Description: Patients will wear bracelets on both hands.
Study: NCT03313102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: sample of 16 blood tubes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: sample of 16 blood tubes
Study: NCT01656837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Community Treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MST-BSF
Study: NCT02304965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily physical activity
Description: A combination of walking (\> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
Study: NCT01290211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: maraviroc 300 mg BID x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 700/100 mg BID x 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Fosamprenavir/ritonavir
Description: maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: maraviroc 300 mg QD x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 1400/100 mg QD x 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Fosamprenavir/ritonavir
Description: maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
Study: NCT02282410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
Study: NCT01919996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
Study: NCT02111785

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burr Hole Craniostomy
Description: Treatment with surgical burr hole craniostomy and evacuation of SDH

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Burr Hole Craniostomy
Description: Treatment with surgical burr hole craniostomy and evacuation of SDH
Study: NCT02358798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 years-assessment of respiratory function
Study: NCT00004011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT04515121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tCES
Description: The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tCES
Description: The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb rehabilitation
Description: Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lower limb rehabilitation
Description: Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
Study: NCT01654991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Screening
Description: Home-based STD screening using self-obtained urine samples and study paid postal return of samples.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Screening
Description: Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
Study: NCT02798211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 300 mg
Description: 150 mg x 2 s.c. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 150 mg
Description: 150 mg s.c. injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01538108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA Balloon catheter with paclitaxel
Description: patients treated by the NMB's PTA Balloon catheter with paclitaxel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plain Balloon angioplasty (PBA)
Description: PBA
Study: NCT03060564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tendon graft
Description: JRF Orthopedics Tendon Graft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT04538989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 Sequential Group Cohort 1
Description: IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 Sequential Group Cohort 2
Description: IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 Sequential Group Cohort 3
Description: IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 Sequential Group Cohort 4
Description: IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
Study: NCT02337517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT02070900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POC CD4
Description: Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programmatic Mentoring
Description: Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors